ThromboGenics NV (THR.BR) News| Reuters.com
Edition:
United States

ThromboGenics NV (THR.BR)

THR.BR on Brussels Stock Exchange

2.92EUR
24 Jun 2016
Change (% chg)

€-0.03 (-1.02%)
Prev Close
€2.95
Open
€2.88
Day's High
€2.95
Day's Low
€2.85
Volume
31,509
Avg. Vol
17,015
52-wk High
€5.47
52-wk Low
€2.71

Select another date:

Wed, Jun 8 2016

BRIEF-Thrombogenics receives FDA approval for JETREA

* Receives US FDA approval for new 'already-diluted' formulation of JETREA

BRIEF-Thrombogenics cash position at end March down at 96.9 mln euros

* Cash and investments were 96.9 million euros as of end of March 2016, vs 101.4 million euros a at end of Dec. 2015 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Thrombogenics says Oncurious and Bioinvent partner with U.S. research consortium

* Says Oncurious NV and Bioinvent partner with U.S. research consortium to accelerate phase I/IIa clinical development of TB-403 Source text: http://bit.ly/251lYUL Further company coverage: (Gdynia Newsroom:)

BRIEF-Thrombogenics enrolls first patient in Phase II CIRCLE Trial

* Announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR)

BRIEF-Thrombogenics gets FDA acceptance of IND for pediatric brain tumors study

* Announces FDA acceptance of investigational new drug (IND) application for a phase I/IIa study with TB-403 for the treatment of pediatric brain tumors

Select another date: